Navigation Links
Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
Date:4/22/2013

San Diego, CA (PRWEB) April 22, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Professors Arshed Quyyumi, MD, FRCP, FACC and Javed Butler, MD, MPH, FACC, FAHA of the Emory Clinical Cardiovascular Research Institute have agreed to join the Scientific Advisory Board for Stemedica’s Cardiology Division.

Dr. Arshed A. Quyyumi has been involved in clinical translational research in cardiovascular diseases for over 25 years. His research focuses on vascular biology, angiogenesis, progenitor cell biology, mechanisms of myocardial ischemia, and the role of genetic and environmental risks on vascular disease. In 2001 he was appointed Professor of Medicine in the Division of Cardiology at the Emory University School of Medicine. In 2010, he was named Co-Director of the Emory Clinical Cardiovascular Research Institute (ECCRI). Dr. Quyyumi serves on the editorial boards of several national journals and is a reviewer for the National Institute of Health’s (NIH) National Heart, Lung and Blood Institute Study Sections. Dr. Quyyumi has authored more than 220 peer-reviewed publications and has been an invited speaker and session chair at many scientific meetings and conferences. During his academic career, Dr. Quyyumi has managed more than 50 NIH, industry-funded, or investigator-initiated projects, including numerous clinical trials.

Dr. Javed Butler’s research focuses on the disease progression, outcomes, and prognosis determination in patients with heart failure, with special emphasis on patients undergoing cardiac transplantation and left ventricular assist device placement. Before moving to Emory University where he is a professor of cardiology, he was Director for the Heart and Heart-Lung Transplant programs at Vanderbilt University. He also serves as the Deputy Chief Science Advisor for the American Heart Association. Additionally, he serves various editorial responsibilities for the Journal of the American College of Cardiology, Journal of Cardiac Failure, American Heart Journal, Journal of the American College of Cardiology – Heart Failure, Heart Failure Clinics, Current Heart Failure Report, and Congestive Heart Failure. He is board certified in Cardiology, Internal Medicine, Advanced Heart Failure and Transplantation Medicine, and Nuclear Cardiology. Dr. Butler also serves on the Executive Council of the Heart Failure Society of America. He has published over 175 peer reviewed papers and has participated in over 50 federally funded and non-federally funded clinical trials. He has served on several steering committees, events committees and data safety monitoring committees for multi-center clinical trials.

Stephen Epstein, M.D., Chairman of the Medical & Scientific Advisory Board for Stemedica’s Cardiology Division, commented, “I am delighted to welcome Drs. Quyyumi and Butler to the cardiology team. I believe our collective breadth of experience will provide Stemedica with both perspective and direction as the company expands its efforts in cardiovascular medicine.”

Stemedica recently formed its Cardiology Division due to the considerable progress in the translational application of its ischemia tolerant adult allogeneic stem cells for cardiovascular diseases. The Company gained FDA approval for a multi-center Phase II clinical trial for intravenous treatment of AMI with its Stemedyne™ MSC product. Regulatory approval has also been granted to the National Medical Research Center in Astana, Kazakhstan for a Phase III trial with Stemedyne™ MSC. A Phase II clinical trial for chronic heart failure has begun at Hospital Angeles in Mexico. The Cardiology Division Scientific Advisory Board was organized to support these and future efforts.

Sergey Sikora, Ph.D., M.D., President of Stemedica’s Cardiovascular Division noted, “Emory has been one of the leaders in cardiology and we are honored to have physicians of Drs. Quyyumi and Butler’s statures participate with us in cardiovascular translational medicine.”

Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica commented, “We are pleased by the impressive and promising outcomes that Stemedica’s adult stem cells are experiencing in cardiology. We view this area as critical for the success of Stemedica and have worked diligently to get the best experts to advise us in this field.”

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/cardiology-Quyyumi-Butler/prweb10655555.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stem cell transplant restores memory, learning in mice
2. UCB and Emory partner to address pressing public health issues for people living with epilepsy
3. Fantastic flash memory combines graphene and molybdenite
4. Self-assembled nanostructures enable a low-power phase-change memory for mobile electronic devices
5. NIST mechanical micro-drum used as quantum memory
6. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
7. UCLA engineers develop new energy-efficient computer memory using magnetic materials
8. Computer memory could increase fivefold from advances in self-assembling polymers
9. Stress breaks loops that hold short-term memory together
10. Future memory
11. Carbon-based transistors ramp up speed and memory for mobile devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... ... SPIE Photonics West conference in San Francisco’s Moscone Center from February 16-18, ... same venue. , These latest InGaAs PIN diode standard packages feature a TO-46 ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells Network ... from the Philippines, Thailand and Singapore in the latest adipose and bone marrow ...
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading ... the Highest Overall Customer Rating Award from Circuits Assembly , today announced its ... the USA, Canada, Mexico and China. , The EMS provider, known in the ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):